{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:25:06Z","timestamp":1765887906599,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There were significant differences in response and pharmacokinetic characteristics to the peginterferon \u03b12a treatment among Chronic Hepatitis B (CHB) patients. The aim of this study is to identify factors which could significantly impact the peginterferon \u03b12a pharmacokinetic characteristics in CHB patients. There were 208 blood samples collected from 178 patients who were considered as CHB and had been treated with peginterferon \u03b12a followed by blood concentration measurement and other laboratory tests. The covariates such as demographic and clinical characteristics of the patients were retrieved from medical records. Nonlinear mixed-effects modeling method was used to develop the population pharmacokinetic model with NONMEM software. A population pharmacokinetic model for peginterferon \u03b12a has been successfully developed which shows that distribution volume (V) was associated with body mass index (BMI), and drug clearance (CL) had a positive correlation with creatinine clearance (CCR). The final population pharmacokinetic model supports the use of BMI and CCR-adjusted dosing in hepatitis B virus patients.<\/jats:p>","DOI":"10.1038\/s41598-017-08205-5","type":"journal-article","created":{"date-parts":[[2017,8,7]],"date-time":"2017-08-07T08:37:20Z","timestamp":1502095040000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Population pharmacokinetics of peginterferon \u03b12a in patients with chronic hepatitis B"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4114-4372","authenticated-orcid":false,"given":"Jingfeng","family":"Bi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanwei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enqiang","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenman","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,11]]},"reference":[{"key":"8205_CR1","unstructured":"Hepatitis B World Health Organization Fact Sheet No 204. http:\/\/www.who.int\/mediacentre\/factsheets\/fs204\/en\/index.html. Accessed 5 May 2017."},{"key":"8205_CR2","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","volume":"384","author":"M Manns","year":"2014","unstructured":"Manns, M. et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet \n                           384, 414\u2013426, doi:10.1016\/S0140-6736(14)60538-9 (2014).","journal-title":"Lancet"},{"key":"8205_CR3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1517\/17425250902787616","volume":"5","author":"E Shudo","year":"2009","unstructured":"Shudo, E., Ribeiro, R. M. & Perelson, A. S. Modeling HCV kinetics under therapy using PK and PD information. Expert Opin Drug Metab Toxicol \n                           5, 321\u2013332, doi:10.1517\/17425250902787616 (2009).","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"8205_CR4","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/hep.24555","volume":"54","author":"YF Liaw","year":"2011","unstructured":"Liaw, Y. F. et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology \n                           54, 1591\u20131599, doi:10.1002\/hep.24555 (2011).","journal-title":"Hepatology"},{"key":"8205_CR5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/01.mpg.0000235974.67496.e6","volume":"43","author":"KB Schwarz","year":"2006","unstructured":"Schwarz, K. B. et al. Safety, efficacy and pharmacokinetics of peginterferon alpha2a (40 kd) in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr \n                           43, 499\u2013505, doi:10.1097\/01.mpg.0000235974.67496.e6 (2006).","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"8205_CR6","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/liv.12254","volume":"34","author":"S Nishiguchi","year":"2014","unstructured":"Nishiguchi, S. et al. Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection. Liver Int \n                           34, 78\u201388, doi:10.1111\/liv.12254 (2014).","journal-title":"Liver Int"},{"key":"8205_CR7","first-page":"93","volume":"11","author":"J Bi","year":"2014","unstructured":"Bi, J. et al. The pharmacokinetics study of PegIFN- alpha -2a in healthy adults. China medical herald (Chinese) \n                           11, 93\u201396 (2014).","journal-title":"China medical herald (Chinese)"},{"key":"8205_CR8","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1016\/j.xphs.2016.08.012","volume":"105","author":"X Li","year":"2016","unstructured":"Li, X. et al. Population Pharmacokinetics of Vancomycin in Postoperative Neurosurgical Patients and the Application in Dosing Recommendation. J Pharm Sci \n                           105, 3425\u20133431, doi:10.1016\/j.xphs.2016.08.012 (2016).","journal-title":"J Pharm Sci"},{"key":"8205_CR9","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.7754\/Clin.Lab.2014.131110","volume":"60","author":"BB Inal","year":"2014","unstructured":"Inal, B. B. et al. Evaluation of MDRD, Cockcroft-Gault, and CKD-EPI formulas in the estimated glomerular filtration rate. Clin Lab \n                           60, 1685\u20131694 (2014).","journal-title":"Clin Lab"},{"key":"8205_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40262-012-0022-9","volume":"52","author":"C Dumont","year":"2013","unstructured":"Dumont, C. et al. Optimal sampling times for a drug and its metabolite using SIMCYP((R)) simulations as prior information. Clin Pharmacokinet \n                           52, 43\u201357, doi:10.1007\/s40262-012-0022-9 (2013).","journal-title":"Clin Pharmacokinet"},{"key":"8205_CR11","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/FTD.0000000000000262","volume":"38","author":"B Imbert","year":"2016","unstructured":"Imbert, B., Marsot, A., Liachenko, N. & Simon, N. Population Pharmacokinetics of High-Dose Oxazepam in Alcohol-Dependent Patients: Is There a Risk of Accumulation? Ther Drug Monit \n                           38, 253\u2013258, doi:10.1097\/FTD.0000000000000262 (2016).","journal-title":"Ther Drug Monit"},{"key":"8205_CR12","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/j.1365-2710.2007.00850.x","volume":"32","author":"D Li","year":"2007","unstructured":"Li, D. et al. Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients. J Clin Pharm Ther \n                           32, 505\u2013515, doi:10.1111\/j.1365-2710.2007.00850.x (2007).","journal-title":"J Clin Pharm Ther"},{"key":"8205_CR13","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1067\/mcp.2001.115872","volume":"69","author":"JF Jen","year":"2001","unstructured":"Jen, J. F. et al. Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C. Clin Pharmacol Ther \n                           69, 407\u2013421 (2001).","journal-title":"Clin Pharmacol Ther"},{"key":"8205_CR14","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1007\/s00228-013-1574-9","volume":"69","author":"C Xu","year":"2013","unstructured":"Xu, C. et al. Population pharmacokinetics of peginterferon alfa-2b in pediatric patients with chronic hepatitis C. Eur J Clin Pharmacol \n                           69, 2045\u20132054, doi:10.1007\/s00228-013-1574-9 (2013).","journal-title":"Eur J Clin Pharmacol"},{"key":"8205_CR15","doi-asserted-by":"crossref","unstructured":"Kempuraj, D. et al. Interleukin-28 and 29 (IL-28 and IL-29): new cytokines with anti-viral activities. Int J Immunopathol Pharmacol \n                           17, 103\u2013106, (2004).","DOI":"10.1177\/039463200401700201"},{"key":"8205_CR16","first-page":"66","volume":"40","author":"Chinese Society of Hepatology of CMA","year":"2012","unstructured":"Chinese Society of Hepatology of CMA. Chinese Society of infectious deseases of CMA. Chinese Journal For Clinicians \n                           40, 66\u201378 (2012).","journal-title":"Chinese Journal For Clinicians"},{"key":"8205_CR17","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/1479-5876-11-240","volume":"11","author":"S Jeon","year":"2013","unstructured":"Jeon, S. et al. Saturable human neopterin response to interferon-alpha assessed by a pharmacokinetic-pharmacodynamic model. J Transl Med \n                           11, 240, doi:10.1186\/1479-5876-11-240 (2013).","journal-title":"J Transl Med"},{"key":"8205_CR18","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1002\/jps.24604","volume":"104","author":"X Li","year":"2015","unstructured":"Li, X. et al. Population Pharmacokinetics of Vancomycin in Postoperative Neurosurgical Patients. J Pharm Sci \n                           104, 3960\u20133967, doi:10.1002\/jps.24604 (2015).","journal-title":"J Pharm Sci"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-08205-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-08205-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-08205-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T08:19:06Z","timestamp":1671783546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-08205-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,11]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["8205"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-08205-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2017,8,11]]},"assertion":[{"value":"14 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"7893"}}